Home  »  Hot Stocks   »  A Lesson to Learn: Reviva Pharmaceuticals Holdings...

A Lesson to Learn: Reviva Pharmaceuticals Holdings Inc. (RVPH)

Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) went down by -4.16% from its latest closing price compared to the recent 1-year high of $6.10. The company’s stock price has collected -4.16% of loss in the last five trading sessions.

Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc. (NASDAQ :RVPH) Right Now?

Plus, the 36-month beta value for RVPH is at 0.18. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Reviva Pharmaceuticals Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

The average price from analysts is $14.00, which is $9.85 above the current price. RVPH currently public float of 14.95M and currently shorts hold a 5.46% ratio of that float. Today, the average trading volume of RVPH was 1.57M shares.

RVPH’s Market Performance

RVPH stocks went down by -4.16% for the week, with a monthly jump of 12.16% and a quarterly performance of 171.24%, while its annual performance rate touched 22.06%. The volatility ratio for the week stands at 9.51% while the volatility levels for the past 30 days are set at 13.85% for Reviva Pharmaceuticals Holdings Inc. The simple moving average for the period of the last 20 days is -7.64% for RVPH stocks with a simple moving average of 102.07% for the last 200 days.

Analysts’ Opinion of RVPH

Many brokerage firms have already submitted their reports for RVPH stocks, with H.C. Wainwright repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on January 24th of the current year 2022.

RVPH Trading at 23.11% from the 50-Day Moving Average

After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.97% of loss for the given period.

Volatility was left at 13.85%, however, over the last 30 days, the volatility rate increased by 9.51%, as shares surge +18.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +89.50% upper at present.

During the last 5 trading sessions, RVPH fell by -4.16%, which changed the moving average for the period of 200-days by +133.15% in comparison to the 20-day moving average, which settled at $4.53. In addition, Reviva Pharmaceuticals Holdings Inc. saw 43.60% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RVPH starting from Patel Purav, who purchase 3,000 shares at the price of $4.69 back on Nov 18. After this action, Patel Purav now owns 43,547 shares of Reviva Pharmaceuticals Holdings Inc., valued at $14,070 using the latest closing price.

Narayan Prabhu, the Chief Financial Officer of Reviva Pharmaceuticals Holdings Inc., purchase 50,000 shares at $1.66 during a trade that took place back on Sep 30, which means that Narayan Prabhu is holding 100,000 shares at $83,000 based on the most recent closing price.

Stock Fundamentals for RVPH

Equity return is now at value -75.90, with -67.20 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 13.39.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]